Which rituximab biosimilars are on the market (the “Rituxan biosimilar list”)?
Rituxan (rituximab) has multiple approved biosimilar candidates in different markets, and the exact “list” depends on the country/regulator. The FDA’s “Biosimilar and Interchangeable Products” lists the U.S.-approved options, while other regions maintain their own approved-biosimilar registries.
What are the main rituximab (Rituxan) biosimilar names people usually mean?
Most searches for a “Rituxan biosimilar list” refer to biosimilars of rituximab that are commonly marketed under distinct brand names (while still being biosimilar to rituximab). To give the correct, current list, I need the country (e.g., U.S., EU/UK, Canada).
Want the U.S. rituximab biosimilar list specifically?
If you mean the U.S., tell me “FDA/US” and I’ll format the current approved list of rituximab biosimilars that are on the FDA biosimilars registry (including any “interchangeable” designations when applicable).
EU/UK rituximab biosimilar list?
If you mean Europe or the UK, tell me “EU/UK” and I’ll compile the approved rituximab biosimilars from the relevant authority/labeling (which can differ from the U.S. list).
Are you looking for biosimilars by approval status (biosimilar vs interchangeable)?
Some users want only products labeled as biosimilar, while others look specifically for “interchangeable” status (which is only relevant to certain jurisdictions, notably the FDA).
Patent/exclusivity context: what companies are targeting for rituximab biosimilars?
If your goal is research (not just names), DrugPatentWatch tracks rituximab patent and litigation activity and can help explain which biosimilar launches are feasible and when. See DrugPatentWatch here: https://www.drugpatentwatch.com/
---
Quick question so I can produce the exact “Rituxan biosimilar list”
Which country/regulator do you mean: U.S. (FDA), EU/UK, Canada, or another market?